Transforming the management of cancer with personalized testing
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for cancer management. This MRD assay is highly sensitive and personalized for each patient, to help inform important treatment decisions.
Knowing earlier matters
Each person’s cancer is as unique as their fingerprint. Signatera is a MRD blood test that is personalized to each patient’s set of tumor mutations and can identify earlier than traditional tools if cancer is still present. Knowing this information can help you have a more informed discussion with your doctor regarding your treatment journey.
How Signatera helps patients through their treatment
Scanxiety is very real for many patients previously diagnosed with cancer. Living scan to scan creates anxiety and fearful thoughts: is the cancer coming back? Through shared decision making, many patients are working closely with their doctors to incorporate Signatera into their treatment plan to provide additional information needed for confident decision making and to provide patients peace of mind between scans. Patient anxiety may be alleviated by gaining a greater understanding of their progress and feel more informed on how they apporach their treatment options.
Listen to Brook Bell’s story, a young CRC patient, discuss her experience using Signatera